Maryland EMTs have new arsenal in fentanyl overdose battle
URBANA, Md. () — Maryland received some help from its General Assembly last week in the fight against the opioid epidemic.
Paramedics now have a new tool to complement naloxone when tending to anyone experiencing a fentanyl overdose: Buprenorphine.
Buprenorphine helps stabilize potential seizures as an overdose victim is transported to the hospital.
Western Maryland YMCAs busiest season kicks off
Montgomery County Delegate Joe Vogel (D-MD17) says lawmakers were unanimous in their support for making the medication available to EMTs.
'For this to work, we need to create a model where, within 24 hours, someone who has experienced an overdose and has been administered Buprenorphine can get into treatment anywhere in the state,' he said.
Vogel says the measure, sent to the governor for his signature last week, will provide training in the administration of the new drug.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Highmark Walk for a Healthy Community takes place at Penn State Behrend
The public was invited to step in to support their favorite non-profit organization. The Highmark Walk for a Healthy Community took place at Penn State Behrend Saturday morning. Ten local non-profits were in attendance, raising money for their own individual missions. Tickets now available Erie Zoo's centennial Mane Event Participants walked either a 5K or one mile and were able to take part in family-friendly activities as well. 'We have the YMCA doing line dancing, we have the walks and all the help, and I love seeing the dogs and children and all the fun,' said Michelle Smiley, the director of the walk. 'We have a scavenger hunt for them, it's just, we have a wonderful day of engagement with the community, it's beautiful.' Smiley said they raised almost $35,000 this year. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
The Coastal Health District offering free HIV testing
SAVANNAH, Ga. (WSAV) – The Coastal Health District HIV Prevention Program is partnering with Walgreens to hold free HIV testing events to commemorate National HIV Testing Day (NHTD). This year's NHTD events will be held on Friday, June 27, at these Walgreens locations in Chatham and Glynn counties: 2109 E. Victory Drive, Savannah: 10 a.m. – 5 p.m. 11509 Abercorn Street, Savannah: 10 a.m. – 3 p.m. 700 E. DeRenne Avenue, Savannah: 10 a.m. – 5 p.m. 4210 Augusta Road, Garden City: 10 a.m. – 3 p.m. 4575 Altama Avenue, Brunswick: 10 a.m. – 3 p.m. According to the Coastal Health District, Georgia has some of the highest HIV rates in the country. Many people living with HIV may not be aware of their status. There are many effective ways to prevent HIV or, if you are infected, to treat HIV so you can live a healthy and full life. But the first step is to know your status. As a reminder, HIV testing is always free by appointment at all health departments in Bryan, Camden, Chatham, Effingham, Glynn, Liberty, Long, and McIntosh counties. Free self-test kits are also available and can be used at home. For more information on the Coastal Health District, click here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory
We came across a bullish thesis on ClearPoint Neuro, Inc. (CLPT) on M.V. Cunha's Substack. In this article, we will summarize the bulls' thesis on CLPT. ClearPoint Neuro, Inc. (CLPT)'s share was trading at $13.93 as of 6th June. A medical doctor surrounded by advanced technology in the operating room. ClearPoint Neuro is transforming from a surgical tools provider into a critical platform company enabling the next generation of neurological treatments. In the first quarter of 2025, revenue grew 31 percent year-over-year to 8.5 million dollars, led by the rapid adoption of its SmartFrame operating room system, which increased 70 percent and allows hospitals to use ClearPoint technology in standard surgical settings. This expansion seeds a larger installed base and drives high-margin recurring revenue from disposable instruments. The biologics and drug delivery segment generated 4.7 million dollars in revenue, growing 9 percent year-over-year, and is supported by more than 60 active partnerships with gene and cell therapy developers. As these therapies move toward commercial use, ClearPoint's role as the enabling delivery infrastructure could become its most profitable revenue stream, with each procedure generating over 20,000 dollars in high-margin recurring revenue. Meanwhile, the company is intentionally moving away from capital equipment sales, which declined 63 percent, in favor of a subscription-based model that provides predictable recurring revenue. Operating cash burn fell 35 percent in 2024, with expenses rising 29 percent in the latest quarter due to targeted investments in preclinical services, therapy support, and device innovation. ClearPoint closed the quarter with 12.4 million dollars in cash and access to up to 105 million dollars in financing, providing sufficient capital to reach financial breakeven without near-term equity dilution. While risks around execution, partner dependency, and regulatory pacing remain, ClearPoint's embedded position across neurological therapy development offers investors a unique opportunity to benefit from a long-term transformation into the backbone of next-generation brain treatments. Previously, we highlighted a on ClearPoint Neuro from northeasternsvf in January 2025, which emphasized its unique position as the only FDA-cleared, MRI-guided neurosurgical platform enabling precise delivery of CNS gene and cell therapies. That thesis focused on the company's expanding biopharma partnerships, operating room penetration through SmartFrame OR, and its path to profitability via high-margin disposables. ClearPoint Neuro, Inc. (CLPT) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held CLPT at the end of the first quarter which was 13 in the previous quarter. While we acknowledge the risk and potential of CLPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CLPT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
